Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
2
33%
Ph phase_2
4
67%

Phase Distribution

2

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
4(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(2)

Detailed Status

Completed4
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (33.3%)
Phase 24 (66.7%)

Trials by Status

withdrawn117%
completed467%
terminated117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

NCT02669511
completedphase_2

Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients

NCT03127020
completedphase_1

PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)

NCT02723877
withdrawnphase_2

PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

NCT03120000
terminatedphase_2

Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients

NCT02850744
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02669511Phase 2

PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Completed
NCT03127020Phase 2

Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients

Completed
NCT02723877Phase 1

PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)

Completed
NCT03120000Phase 2

PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Withdrawn
NCT02850744Phase 2

Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients

Terminated
NCT01940133Phase 1

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6